Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2010

View Archived Issues

Endece's novel ER agonists block chromosome replication and show antitumor activity in vivo

Actelion claims novel calcium channel blockers

INS-115644 reduces IOP in glaucoma, ocular hypertension patients

Novel antifungal agents identified by Indian scientists

Bristol-Myers Squibb claims novel MCH-R1 antagonists

Basilea Pharmaceutica's novel tubulin polymerization inhibitors show promising preclinical activity

Novel anti-PLGF murine monoclonal antibody P-16 displays potent antitumor activity in vivo

Presidio reports preclinical data on its novel HCV NS5A inhibitor PPI-461

VAX-102 increases immune response to trivalent influenza vaccine

Promising phase II data on JX-594 in HCC support phase III evaluation

Chimerix initiates first-in-human phase I study of CMX-157

Array BioPharma discloses novel Trk kinase inhibitors

DMC recommends continuation of phase III ThermoDox HEAT study

Merck & Co. identifies novel orexin receptor antagonists

Repligen files IND with FDA for Friedreich's ataxia drug

Meda acquires European rights from Graceway to new imiquimod formulation for AK

Rexahn to move forward with phase IIb trial of Zoraxel for ED

Octapharma launches Wilate for von Willebrand disease

FDA assigns November 4, 2010 action date for Cadence's Ofirmev NDA

Roche to begin study of TB-403 in patients with colorectal and ovarian cancer

Amgen submits BLA for denosumab for skeletal-related events in cancer patients

SRI International's SR-16388 has promise for multiple myeloma

Astellas to acquire OSI Pharmaceuticals

FDA recommends resumption of use of Rotarix

Lundbeck announces results of pivotal Japanese study of escitalopram

SciClone provides update on clinical program for SCV-07 in oral mucositis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...